BlackRock’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

BlackRock’s Portfolio ARLZ Stock Details ARLZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-996,056	Closed	-$2.28M	–	5127
2017 Q3	$2.28M	Buy	996,056 +8,838	+0.9%	+$11.8K	﹤0.01%	3674
2017 Q2	$1.33M	Buy	987,218 +75,341	+8%	+$109K	﹤0.01%	3778
2017 Q1	$1.95M	Buy	+911,877	New	+$3.43M	﹤0.01%	3657
2016 Q2	–	Sell	-2,946	Closed	-$10K	–	3953
2016 Q1	$10K	Buy	+2,946	New	+$15.2K	﹤0.01%	3185

Other funds holding ARLZ

PCM

PAR Capital Management Boston, Massachusetts $3.45B AUM 28.5% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BMCM

Bryn Mawr Capital Management Philadelphia, Pennsylvania $2.06B AUM 19.82% 1-Year Est. Return

BlackRock's ARLZ Position: Q4 2017 in Review

BlackRock sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q4 2017, closing a stake of 996,056 shares — an estimated $2.28M sold.

BlackRock first reported a position in ARLZ in Q1 2016 and held it in 4 quarters. The position peaked at $2.28M in Q3 2017. 63 funds tracked by Wall St. Rank hold ARLZ as of Q4 2017.

BlackRock reported no remaining Aralez Pharmaceuticals Inc. position as of Q4 2017 after selling out during the quarter.
BlackRock sold 996,056 Aralez Pharmaceuticals Inc. shares in Q4 2017, an estimated $2.28M.
BlackRock first reported a position in Aralez Pharmaceuticals Inc. in Q1 2016 and held it in 4 quarters.
BlackRock's Aralez Pharmaceuticals Inc. position peaked at $2.28M in Q3 2017.
63 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q4 2017.

Based on BlackRock's 13F filing for Q4 2017, filed 9 Feb 2018.